The clinical significance signal lymph node biopsy using indocyanine green after effective neoadjuvant chemotherapy with target therapy with early sporadic early HER2 positive breast cancer

• DOI: 10.20340/vmi-rvz.2025.1.clin.5
• Publication Date: 2025-04-08T10:28:12Z
• Authors: K. S. Titov; I. N. Kuts; D. A. Karseladze; I. N. Lebedinskiy; Z. V. Lorie; S. S. Lebedev; D. N. Grekov

According to the International Agency for Research on Cancer GLOBOCAN (Cancer Today), breast cancer ranks first in the structure of mortality from cancer among women. In recent decades, there has been a steady trend in the treatment of breast cancer to minimize the volume of radical surgical treatment in order to improve the quality of patients lives and comply with the principles of oncological adequacy. A sentinel lymph node biopsy (SLNB) is an alternative to axillary lymphatic dissection in patients with clinically intact regional lymph nodes (cN0). This allows patients to avoid such formidable and often disabling complications of lymphatic dissection as – prolonged postoperative lymphorrhea and lymphatic swelling of the upper extremity (lymphostasis). Thanks to SLNB in combination with neoadjuvant therapy (NAT), which is most effective in HER2-positive tumors, the number of patients who underwent organ-preservation surgical treatment is steadily increasing. World trends go further and in the range of studies an attempt to abandon the implementation of SLNB has already been made in some groups of patients with early breast cancer. This article analyzes the experience and results of performing a fluorescent signal lymph node biopsy using indocyanine green after effective neoadjuvant polychemotherapy with target therapy in patients with early sporadic HER2-positive breast cancer in the oncology department of Botkin Hospital.